Humulin R (Insulin Human)

Humulin R is indicated for the management of hyperglycemia in patients with diabetes mellitus.

• Type 1 diabetes mellitus (adults and children)
• Type 2 diabetes mellitus (when diet, exercise, and oral agents are insufficient)
• Use as a mealtime (prandial) insulin to control post‑prandial glucose spikes
• Supplemental insulin in insulin pump therapy or basal‑bolus regimens
• Hospitalized patients requiring rapid glucose control via intravenous infusion

• Humulin R provides exogenous insulin that binds to insulin receptors on the surface of muscle, adipose, and hepatic cells. Receptor activation triggers autophosphorylation of the β‑subunit and initiates intracellular signaling cascades, notably the phosphatidylinositol‑3‑kinase (PI3K)/Akt pathway. This cascade promotes translocation of GLUT‑4 glucose transporters to the cell membrane, enhances glycogen synthesis, suppresses hepatic gluconeogenesis, and facilitates cellular uptake and utilization of glucose, thereby lowering blood glucose concentrations.

Adverse reactions to Humulin R may vary in frequency and severity. Reported events are grouped below.

Common

• Mild hypoglycemia (low blood glucose)
• Injection site redness, swelling, or itching
• Lipodystrophy (localized fat loss or accumulation)
• Transient nausea or abdominal discomfort

Serious

• Severe hypoglycemia with loss of consciousness or seizures
• Allergic reactions such as urticaria, angioedema, or anaphylaxis
• Acute metabolic acidosis (rare)

Clinicians should consider several precautions when prescribing Humulin R to ensure safe and effective use.

• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose closely when initiating therapy or modifying the regimen.
• Use lower initial doses in elderly patients or those with renal or hepatic impairment.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Counsel patients on recognizing and treating hypoglycemia promptly.
• Consider pregnancy status; insulin requirements may change during gestation.

Humulin R can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require dose changes.
• Diuretics, especially loop diuretics, that can alter electrolyte balance and insulin sensitivity.
• Alcohol consumption, which can cause delayed hypoglycemia.